18 results about "Fasudil" patented technology

A method includes treatment of a sporadic ALS patient with oral fasudil at a dose exceeding 240 mg / day. This results in an anticipated 25-50% reduction in the average decline over at least three months as measured using the revised ALS Functional Rating Scale.

The present invention provides a culture medium for primary ovarian cancer cells, an in vitro culture method, and applications thereof. The culture medium comprises an MST1 / 2 kinase inhibitor; at least one Rho protein kinase inhibitor selected from Y27632, fasudil, and H-1152; an insulin-transferrin-selenium supplement; insulin; prostaglandin E2; epidermal growth factor; gastrin; insulin-like growth factor-1; cholera toxin; amphiregulin; N2; and B27. Compared to existing culture methods, in vitro culture using the culture medium of the present invention has higher expansion efficiency. Culturing primary ovarian cancer cells using this culture medium can maintain the morphological structure and pathological characteristics of the primary tissue, thereby improving the success rate and survival rate of primary ovarian cancer cell culture.

A method for treating patients with NOTCH3 mutations using a rho kinase inhibitor has been disclosed. Abnormal NOTCH3 signaling is a pathological factor in cerebral small vessel diseases, including CADASIL. A preferred embodiment relates to treating patients orally with the rho kinase inhibitor fasudil or its active metabolite hydroxyfasudil.

The application provides a culture medium and a culture method of a gastric cancer organoid. The culture medium comprises an MST1 / 2 kinase inhibitor, a fibroblast growth factor 7, R-spondin 1, hydrocortisone, a B27 supplement, an N2 supplement, insulin, a dual regulatory protein, at least one Rho protein kinase inhibitor selected from Y27632, fasudil and H-1152, forskolin, gastrin, fetal bovine serum and cholera toxin. Compared with the existing culture method, the in-vitro culture using the culture medium has higher amplification efficiency; the culture of the gastric cancer organoid using the culture medium can maintain the morphological structure and pathological characteristics of the primary tissue, and improve the success rate and survival rate of the gastric cancer organoid culture.

Disclosed are methods of treating patients with AD using a rho kinase inhibitor. A preferred rho kinase inhibitor used according to the invention is fasudil, which is typically administered orally in a total daily dose of 70-140 mg. A preferred dosing regimen involves administering the daily dose in three equal portions throughout the day. Preferred methods continue for more than one month and typically at least 2 or 3 months. Some preferred methods do not treat mild cognitive impairment and patients have and MMSE score of ≤23 and / or a CDR-SOB score of ≥4.5.

The invention relates to the technical field of traditional Chinese medicine, in particular to a Zhenwu decoction combined preparation as well as a preparation method and application thereof. The Zhenwu decoction combined preparation comprises Zhenwu decoction drug-containing serum and fasudil. In the Zhenwu decoction combined preparation, ZWT of drug-containing serum of the Zhenwu decoction can improve renal function impairment in CGN and inhibit mesangial cell proliferation and inflammatory response by inhibiting RhoA / ROCK / MLC signal channels; the combination of ZWT and Fasudil can synergistically inhibit MC proliferation and promote apoptosis, and has a potential value in CGN treatment.

This invention provides the application of fasudil in the preparation of a drug for the prevention and / or treatment of neuropathic pain following spinal cord injury, relating to the field of pharmaceutical technology. Experimental data show that fasudil can significantly improve the pain behavior of rats with spinal cord injury, and its mechanism of action may be related to the inhibition of Rho / ROCK signaling pathway activation. Further studies have found that fasudil intervention during the acute phase of spinal cord injury can produce a relatively long-lasting analgesic effect, showing promising application prospects.

Disclosed herein are formulations of fasudil and methods for using the same to treat neurological conditions such as ALS.

The invention discloses a fasudil derivative compound and a pharmaceutically acceptable salt of the fasudil derivative compound. The fasudil derivative compound disclosed by the invention can play a therapeutic role in protecting cerebral ischemia injury, has an important potential therapeutic value, and can be used for preparing medicines for treating cerebral apoplexy diseases.

The present invention provides a culture medium for primary intestinal cancer cells, an in vitro culture method, and applications thereof. The culture medium comprises an MST1 / 2 kinase inhibitor; insulin; a Rho protein kinase inhibitor selected from at least one of Y27632, fasudil, and H-1152; an insulin-transferrin-selenium supplement; a glutamine additive; neuregulin 1; a bovine pituitary extract; basic fibroblast growth factor; R-spondin 1; prostaglandin E2; and B27. Compared to existing culture methods, in vitro culture using the culture medium of the present invention has higher amplification efficiency. Using this culture medium for primary intestinal cancer cells can maintain the morphological structure and pathological characteristics of the primary tissue, thereby improving the success rate and survival rate of primary intestinal cancer cell culture.

A method of treating a patient having a NOTCH3 mutation with an rho kinase inhibitor is disclosed. Abnormal NOTCH3 signaling is a pathological participant in small vascular cerebrovascular diseases, including CADASIL. A preferred aspect relates to the treatment of a patient in an oral manner with said rho kinase inhibitor, i.e., fasudil, or an active metabolite thereof, i.e., hydroxyfasudil.

Disclosed herein are sublingual formulations of fasudil and methods for using the same to treat neurological conditions such as ALS.

The present invention provides a culture medium and a culture method for intestinal cancer organoids. The culture medium comprises an MST1 / 2 kinase inhibitor; a B27 additive; an N2 additive; insulin; A8301; human fibroblast growth factor-10; neuregulin-1; amphiregulin; at least one Rho protein kinase inhibitor selected from Y27632, fasudil, and H-1152; fetal bovine serum; basic fibroblast growth factor; insulin-like growth factor-1; forsklin; bovine pituitary extract; and fibroblast growth factor 7. Compared with existing culture methods, in vitro culture using the culture medium of the present invention has higher expansion efficiency. Cultivating intestinal cancer organoids using this culture medium can maintain the morphological structure and pathological characteristics of the original tissue, thereby improving the success rate and survival rate of intestinal cancer organoid culture.

The present application provides a culture medium for culturing primary cervical cancer cells and a culture method using the primary cell culture medium and applications thereof. The culture medium comprises an MST1 / 2 kinase inhibitor; an insulin-like growth factor 1; a fibroblast growth factor 7; an insulin-transferrin-selenium complex; a hepatocyte growth factor; a ROCK kinase inhibitor selected from at least one of Y27632, fasudil, and H-1152; and liothyronine. In the culture method, the primary cells are cultured on a culture vessel pre-coated with irradiated feeder cells using the primary cell culture medium described above, so that the primary cells proliferate rapidly. The cell model obtained by the primary cell culture medium and the primary cell culture method of the present application can be used for efficacy evaluation and screening of drugs.

An oral pharmaceutical composition is provided that can comprise a rho kinase inhibitor, for example, fasudil, a pharmaceutically acceptable salt thereof, a hydrate thereof, a prodrug thereof, a substituted derivative thereof, or a metabolite thereof, or any combination thereof, the rho kinase inhibitor having a bitter taste; and an ion exchange resin. The ion exchange resin can partially or fully mask the bitter taste of the rho kinase inhibitor, making the composition more palatable. The composition can comprise a solid dosage form, and / or a liquid dosage form. The solid dosage form can comprise a powder, granules, a tablet, or a capsule, or any combination thereof. The composition can be present, for example, in a unit dose, in an amount sufficient to treat a neurodegenerative disease. A method of treating the neurodegenerative disease with the oral pharmaceutical composition is provided. The method can ameliorate a symptom of a neurodegenerative disease.

The present invention relates to the treatment of an ALS patient having disease onset of at least 24 months prior to initiation of treatment with fasudil. Fasudil is administered at a dose of 60-240 mg / day according to specific treatment regimens. This results in an anticipated 25-50% reduction in the average decline over at least three months as measured using the revised ALS Functional Rating Scale.

To provide preventive and / or therapeutic treatment for combating dyskinesias with fewer side effects and more effects.SOLUTION: Provided herein is a pharmaceutical composition comprising an inhibitor of ROCK pathway for use in preventive and / or therapeutic treatment of L-dopa-induced dyskinesia. The inhibitor is selected from fasudil and derivatives thereof, ripasudil, Y-27632, Y-32885, AMA-0076, AR-12286, AR-13324 (Rhopressa), KD-025 (Slx2119), LX7101, PG-324 (Roclatan) and SAR407899.SELECTED DRAWING: Figure 2-1